Table 3 Multivariate analysis for overall survival
From: Outcome of therapy-related myeloid neoplasms treated with azacitidine
Hazard Ratio | p | 95% C.I. | |
|---|---|---|---|
WHO type (t-AML vs t-MDS) | 3.49 | 0.03 | 1.17-10.46 |
Karyotype (aberrant versus normal) | 2.2 | 0.015 | 0.75-6.58 |
Front-line AZA (no vs yes) | 3.45 | 0.08 | 0.87-13.62 |